Brigham and Women's Hospital Articles

Oncology Advances January 2017

Receive news, treatment options, research and clinical trials from Brigham and Women's Cancer Center

Issue link: http://brighamandwomens.uberflip.com/i/748899

Contents of this Issue

Navigation

Page 6 of 7

Dana-Farber/Brigham and Women's Cancer Center | 7 For More Information, Consultation and Referral Dana-Farber/Brigham and Women's Cancer Center is easy to access at 1-877-332-4294, Monday through Friday, 8 a.m. to 6 p.m. Dana-Farber/Brigham and Women's Cancer Center in Boston offers next business day access for first appointments. To facilitate this streamlined access, patients who are scheduled for next day access are contacted within a few hours by an oncology nurse to discuss their history and records. To refer a patient, or schedule a consultation with a member of our team, please call 1-877-332-4294. Next Day Access for New Oncology Patients Ronald Bleday, MD Chief, Division of Colon and Rectal Surgery, Brigham and Women's Hospital; Surgical Director, Colon and Rectal Cancer Center, Dana-Farber/Brigham and Women's Cancer Center Mark A. Preston, MD, MPH Division of Urology, Brigham and Women's Hospital; Lank Center for Genitourinary Oncology, Dana-Farber/Brigham and Women's Cancer Center The ERAS Protocol Image courtesy of the ERAS ® Society ERAS is a multimodal perioperative care pathway designed to achieve early recovery for patients undergoing major surgery. The protocol focuses on optimizing care at each stage of the process through the coordinated efforts of surgeons, anesthesiologists, physician assistants, nurses, and many other members of the patient's care team. Key aspects of the protocol include the avoidance of bowel preparation and fasting in the pre-operative period and faster return to solid foods, early ambulation, and use of non- opioid pain medications in the postoperative period. precisioncancermedicine.org Dana-Farber/Brigham and Women's Cancer Center offers an online resource to provide information on precision cancer medicine, including: • Latest thinking in precision cancer medicine from our researchers and clinicians, including specialized information in key diseases • A searchable database of clinical trials that focus on targeted ther- apies by disease, gene and mutation • Genomic research studies and findings, including information on Profile, our large scale cohort, where over 13,800 tumor profiles have been generated, testing for mutations, insertions and dele- tions, copy number changes, and rearrangements involving more than 300 genes. • Referral and access information

Articles in this issue

Links on this page

view archives of Brigham and Women's Hospital Articles - Oncology Advances January 2017